Vor Biopharma Inc.

Vor Biopharma Inc.

VOR · Nasdaq

Vor Biopharma Inc. (VOR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq. This page provides the complete earnings calendar, dividend schedule, and financial data for Vor Biopharma Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 81 days

EPS estimate

-0.81

Revenue estimate

0

Past earnings

11 Aug 2026
EPS actual
-1.16 (-21.2%)
estimate -0.96
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
11 May 2026
EPS actual
—
estimate -0.78
Revenue actual
—
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
30 Mar 2026
EPS actual
52.28 (+233.5%)
estimate 15.67
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
13 Nov 2025
EPS actual
-121.63 (-3,423.0%)
estimate -3.45
Revenue actual
0
estimate 0
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

Vor Biopharma Inc. missed consensus estimates in its latest earnings report, with EPS of -$1.16 versus an estimate of -$0.9571, and revenue met expectations at $0. In the prior quarter EPS was 233.5% above expectations while revenue met estimates.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Exchange
Nasdaq
CEO
Jean-Paul Kress
Employees
159
IPO date
05 Feb 2021
ISIN
US9290332074
Website
vorbio.com

Frequently asked questions

When does Vor Biopharma Inc. (VOR) next report earnings?

Vor Biopharma Inc. (VOR) is scheduled to report earnings on November 11, 2026.

What was Vor Biopharma Inc.'s most recent earnings date?

Vor Biopharma Inc. (VOR) last reported earnings on August 11, 2026.

Where is Vor Biopharma Inc. stock listed?

Vor Biopharma Inc. (VOR) is listed on Nasdaq.